EUVIMEDEUVIMED entdecken
Crossref

Invitro activity of gemifloxacin against some clinical bacterial isolates of urinary tract infections

Ching Fidelis Poh, J. G. CHIMECHEFULAM

Afrischolar Discovery · 16.11.2023

DOI: 10.60787/wapcp-23-2-10 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Afrischolar Discovery, erschienen am 16.11.2023. Verfasst von Ching Fidelis Poh und 1 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gemifloxacin is a third generation fluoroquinolone with broad spectrum antimicrobial and enhanced activity against both aerobic and anaerobic Gram positive bacteria. It is recommended for the treatment of respiratory tract infections.

Objectives

This study evaluated and compared the antibacterial activity of gemifloxacin with ciprofloxacin, ofloxacin and norfloxacin using minimum inhibition concentration assays against Staphylococcus aureus, Escherichia coli, Alcaligenes faecalis, Pseudomonas aeruginosa, Serratia marcescens, Enterobacter aerogenes, Proteus vulgaris and Klebseilla pneumoniae obtained from urine samples of patients.

Methods

The minimum inhibition concentration (MIC) evaluations were employed for the comparative studies and zones of inhibition assay were further used to determine the antibacterial activity of gemifloxacin. For the MIC evaluations, final nutrient agar concentrations of 5, 7.5, 10, 15, 20, 25 and 30µg/ml of gemifloxacin, ciprofloxacin, ofloxacin, and norfloxacin were used. For the zones of inhibition assay, 0.2ml of the MICs (7.5, 10, 15, 25 and 30 µg/ml) of gemifloxacin against particular bacterium was used.

Results

The MICs of gemifloxacin were 7.5µg/ml for Proteus vulgaris, 10µg/ml for Staphylococcus aureus and Enterobacter aerogenes, 15µg/ml for E. coli, 20µg/ml for Pseudomonas aeruginosa, 25µg/ml for Klebsiella pneumonia and 30µg/ml for Alcaligenes faecalis and Serratia marcescens. The clinical isolates were most sensitive to ofloxacin with MICs of 7.5µg/ml for Proteus vulgaris and 10µg/ml for the other isolates. The isolates were least susceptible to norfloxacin with MICs of 10µg/ml for Proteus vulgaris and 30µg/ml for the other isolates. The results show that the clinical isolates were most sensitive to ofloxacin followed by gemifloxacin, ciprofloxacin and norfloxacin respectively.

Conclusion

Although gemifloxacin is not currently strongly recommended for urinary tract infections, this study has shown that it possesses antibacterial activity against the clinical isolates obtained from urine samples of patients with urinary tract infections and could have a place in the treatment of urinary tract infections caused by the organisms. Key words: Gemifloxacin, urinary tract infections, invitro activity.

Schlagwörter

gemifloxacinurinary tract infectionfluoroquinolonesantibacterial activityminimum inhibitory concentrationciprofloxacinofloxacinnorfloxacinStaphylococcus aureusEscherichia coli

Zitieren

APA

Poh, C. F., & CHIMECHEFULAM, J. G. (2023). Invitro activity of gemifloxacin against some clinical bacterial isolates of urinary tract infections. Afrischolar Discovery. https://doi.org/10.60787/wapcp-23-2-10

Vancouver

Poh CF, CHIMECHEFULAM JG. Invitro activity of gemifloxacin against some clinical bacterial isolates of urinary tract infections. Afrischolar Discovery. 2023. doi:10.60787/wapcp-23-2-10

BibTeX
@article{Poh2023,
  author = {Poh, Ching Fidelis and CHIMECHEFULAM, J. G.},
  title = {Invitro activity of gemifloxacin against some clinical bacterial isolates of urinary tract infections},
  journal = {Afrischolar Discovery},
  year = {2023},
  doi = {10.60787/wapcp-23-2-10}
}
Kostenlos starten →